Grants

PI Name PI Organization Title Grant Number Initiative Program Director
Cocucci, Emanuele

Ohio State University
United States

 A SYNTHETIC BIOMARKER TO UNIVERSALLY ASSESS THE RELATIVE CONTRIBUTION OF HEATHY AND CANCEROUS TISSUE TO CIRCULATING EV POOL 1R01CA270251-01A1 PAR-20-053 (R01 Clinical Trial Not Allowed) Matthew Young, Ph.D.
Cooperberg, Matthew R

University Of California, San Francisco
United States

 Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment 5R01CA198145-05 Richard Mazurchuk, Ph.D.
Counter, Christopher M

Duke University
United States

 PROMINENT-DUKE 1OT2CA278661-01 Sharmistha Ghosh-Janjigian, Ph.D.
Counter, Christopher M

Duke University
United States

 Adapting K-MDS to detect KRAS-mutant ctDNA 1R21CA257816-01A1 RFA-CA-21-003 (R21 Clinical Trial Not Allowed) Lynn Sorbara, Ph.D.
Darie, Costel C.

Clarkson University
United States

 PA-21-071 for Pathea Bruno to CA260126-01 Identifying a proteomic signature for breast cancer detection in breast milk and serum 3R15CA260126-01A1S1 Sharmistha Ghosh-Janjigian, Ph.D.
Deng, Youping

University Of Hawaii At Manoa
United States

 Profiling genome-wide circulating ncRNAs for the early detection of lung cancer 5R01CA223490-05 Lynn Sorbara, Ph.D.
Deng, Youping

University Of Hawaii At Manoa
United States

 Circulating lipid and miRNA markers for early detection of breast cancer among women with abnormal mammograms 5R01CA230514-04 Christos Patriotis, Ph.D., M.Sc.
Dong, Wen-Ji

Washington State University
United States

 Two-Dimensional Multi-Stage Isotachophoretic Technology for Multiplex Analysis of Cancer Exosomes and Proteins Marker Panel 5R21CA248734-02 Matthew Young, Ph.D.
Drake, Richard R.

Medical University Of South Carolina
United States

 Targeted Isolation and Identification of Sialylated Glycoproteins in Cancer Tissues, Cells and Biofluids 5R33CA267226-02 RFA-CA-21-004 (R33 Clinical Trial Not Allowed)
Duncavage, Eric J

Washington University
United States

 Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic Syndromes 1UH2CA272904-01 PAR-20-313 (UH2/UH3 Clinical Trial Not Allowed) Lynn Sorbara, Ph.D.